Study 22 of 24Vasopressin literatureJAMATop journal2026
Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: Research Summary.
Not reported in abstract.
Where it sits
this study against the rest of the vasopressin corpus3
Preclinical · this one
18
Observational
1
Open-label
1
Randomised
1
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Vasopressin corpus
CDesign of liquid crystalline nanoparticles: Linking composition to membrane interactions and siRNA delivery.International journal of pharmaceutics: X · 2026 · siRNA delivered by LCN-P407 showed > 1.7-fold greater uptake than that administered by LCN-P188.In vitroCFetal microglia show region-specific and morphology-dependent sex differences in their responsiveness to prenatal maternal stressbiorxiv-preprint · 2026 · Not reported in abstract.AnimalDArginine Treatment and Sickle Cell Disease Pain-A Great STArT, but a Hard End Point.JAMA · 2026—BArginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.JAMA · 2026HumanCActivation of Vasopressin Receptor 1A by Vasopressin Enhances Myometrial Smooth Muscle Cell Excitability by Inhibiting the Potassium Channel SLO2.1biorxiv-preprint · 2026 · SLO2.1-mediated potassium currents reduced to approximately 60% of control currents.In vitroCInhibition of the Notch signaling pathway promotes AQP2 plasma membrane accumulation in renal epithelial cells by depolymerizing actin and reducing endocytosisbiorxiv-preprint · 2026 · 60% reduction in clathrin-mediated endocytosis.In vitro